Fig. 1From: Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case reportThe clinical course of the case. 1) The 23rd administration of the primary therapy (containing bevacizumab) on day − 28. 2) The first administration of the secondary therapy (containing ramucirumab) on day 1. 3) The second administration of the secondary therapy (containing ramucirumab) on day 22. 4) Renal biopsy on day 45Back to article page